Protein defects in neuromuscular diseases

M. Vainzof and M. Zatz

Centro de Estudos do Genoma Humano, Departamento de Biologia, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, Brasil

Abstract

Muscular dystrophies are a heterogeneous group of genetically determined progressive disorders of the muscle with a primary or predominant involvement of the pelvic or shoulder girdle musculature. The clinical course is highly variable, ranging from severe congenital forms with rapid progression to milder forms with later onset and a slower course. In recent years, several proteins from the sarcoplasma membrane (dystrophin, sarcoglycans, dysferlin, cavelon-3), from the extracellular matrix (α2-laminin, collagen VI), from the sarcomere (telethonin, myotilin, titin, nebulin), from the muscle cytosol (calpain 3, TRIM32), from the nucleus (emerin, lamin A/C, survival motor neuron protein), and from the glycosylation pathway (fukutin, fukutin-related protein) have been identified. Mutations in their respective genes are responsible for different forms of neuromuscular diseases. Protein analysis using Western blotting or immunohistochemistry with specific antibodies is of the utmost importance for the differential diagnosis and elucidation of the physiopathology of each genetic disorder involved. Recent molecular studies have shown clinical inter- and intra-familial variability in several genetic disorders highlighting the importance of other factors in determining phenotypic expression and the role of possible modifying genes and protein interactions. Developmental studies can help elucidate the mechanism of normal muscle formation and thus muscle regeneration. In the last fifteen years, our research has focused on muscle protein expression, localization and possible interactions in patients affected by different forms of muscular dystrophies. The main objective of this review is to summarize the most recent findings in the field and our own contributions.

Introduction

Protein studies are of the utmost importance for enhancing our understanding of genotype/phenotype correlations, as well as for diagnostic purposes, in particular in neuromuscular disorders, in which many genes are involved. Different approaches have been used to study proteins such as detection, quantification and localization by reaction with specific antibodies and assays for specific biological activities. Protein studies by analysis of the status of different components of muscle fibers are of the utmost importance for the differential diagnosis and elucidation of the physiopathology of these diseases. This review will focus on the most recent findings in protein analysis and on our own studies of the Brazilian population.

At least 30 different forms of muscular
dystrophy have been identified to date. Duchenne (DMD) and Becker (BMD) muscular dystrophies are allelic conditions caused by mutations in the dystrophin gene at Xp21 (1,2) (see Table 1). The limb-girdle muscular dystrophies (LGMD) include a heterogeneous group of progressive disorders mainly affecting the pelvic and shoulder girdle musculature, ranging from severe forms with onset in the first decade of life and rapid

<table>
<thead>
<tr>
<th>Group of proteins</th>
<th>Proximal muscular dystrophy phenotypes</th>
<th>Mode of inheritance</th>
<th>Gene location</th>
<th>MIM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma membrane</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dystrophin</td>
<td>DMD/BMD</td>
<td>XL</td>
<td>Xp21</td>
<td>310200</td>
</tr>
<tr>
<td>α-Sarcoglycan</td>
<td>LGMD2D</td>
<td>AR</td>
<td>17q12</td>
<td>600119</td>
</tr>
<tr>
<td>β-Sarcoglycan</td>
<td>LGMD2E</td>
<td>AR</td>
<td>4q12</td>
<td>604286</td>
</tr>
<tr>
<td>γ-Sarcoglycan</td>
<td>LGMD2C</td>
<td>AR</td>
<td>13q12</td>
<td>253700</td>
</tr>
<tr>
<td>δ-Sarcoglycan</td>
<td>LGMD2F</td>
<td>AR</td>
<td>5q33-34</td>
<td>601287</td>
</tr>
<tr>
<td>Dysferlin</td>
<td>LGMD2B/Miyoshi myopathy</td>
<td>AR</td>
<td>2p13</td>
<td>253601</td>
</tr>
<tr>
<td>Caveolin-3</td>
<td>LGMD1C</td>
<td>AD</td>
<td>3p25</td>
<td>601253</td>
</tr>
<tr>
<td>Extracellular matrix</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α2-Laminin</td>
<td>Merosin-deficient CMD</td>
<td>AR</td>
<td>6q2</td>
<td>156225</td>
</tr>
<tr>
<td>Collagen VI</td>
<td>Ulrich CMD, Bethlem myopathy</td>
<td>AR</td>
<td>21q22</td>
<td>254090</td>
</tr>
<tr>
<td>Cytosolic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calpain 3</td>
<td>LGMD2A</td>
<td>AR</td>
<td>15q15.1</td>
<td>253600</td>
</tr>
<tr>
<td>TRIM32</td>
<td>LGMD2H</td>
<td>AR</td>
<td>9q31-34</td>
<td>254110</td>
</tr>
<tr>
<td>Myotubularin</td>
<td>Myotubular myopathy</td>
<td>XL</td>
<td>Xq28</td>
<td>310400</td>
</tr>
<tr>
<td>Involved in glycosylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fukutin</td>
<td>Fukuyama CMD</td>
<td>AR</td>
<td>9q31-33</td>
<td>253800</td>
</tr>
<tr>
<td>FKRP</td>
<td>LGMD2J/CMDC</td>
<td>AR</td>
<td>19q1</td>
<td>606596</td>
</tr>
<tr>
<td>POMFNT1</td>
<td>Muscle-eye-brain CMD</td>
<td>AR</td>
<td>1p32-34</td>
<td>253280</td>
</tr>
<tr>
<td>POMT1</td>
<td>Walker-Warburg CMD</td>
<td>AR</td>
<td>9q34</td>
<td>236670</td>
</tr>
<tr>
<td>Sarcomeric proteins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titin</td>
<td>LGMD2J</td>
<td>AR</td>
<td>2q</td>
<td>101800</td>
</tr>
<tr>
<td>Myotilin</td>
<td>LGMD1A</td>
<td>AD</td>
<td>5q22-34</td>
<td>159000</td>
</tr>
<tr>
<td>Telethonin</td>
<td>LGMD2G</td>
<td>AR</td>
<td>17q11-12</td>
<td>601954</td>
</tr>
<tr>
<td>Actin</td>
<td>Nemaline myopathy</td>
<td>AD/AR</td>
<td>1q42</td>
<td>256030</td>
</tr>
<tr>
<td>Tropomyosin 3</td>
<td>Nemaline myopathy</td>
<td>AD/AR</td>
<td>1q21-23</td>
<td>161800</td>
</tr>
<tr>
<td>Tropomyosin 2</td>
<td>Nemaline myopathy</td>
<td>AD</td>
<td>9p13</td>
<td>190990</td>
</tr>
<tr>
<td>Nebulin</td>
<td>Nemaline myopathy</td>
<td>AD</td>
<td>2q21-22</td>
<td>256030</td>
</tr>
<tr>
<td>Troponin T1</td>
<td>Nemaline myopathy</td>
<td>AD</td>
<td>19q13</td>
<td>190990</td>
</tr>
<tr>
<td>Nuclear proteins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emerin</td>
<td>Emery-Dreifuss MD</td>
<td>XL</td>
<td>Xq28</td>
<td>310300</td>
</tr>
<tr>
<td>Lamin A/C</td>
<td>LGMD1B</td>
<td>AD</td>
<td>1q11-21</td>
<td>159001</td>
</tr>
<tr>
<td>SMN</td>
<td>Spinal muscular atrophy</td>
<td>AR</td>
<td>5q11-13</td>
<td>253300</td>
</tr>
</tbody>
</table>

AD/AR - autosomal dominant and recessive inheritance; BMD - Becker muscular dystrophy; CMD - congenital MD; DMD - Duchenne MD; FKRP - Fukutin-related protein; LGMD - limb-girdle MD; SMN - survival motor neuron protein; XL - X-linked inheritance. MIM number - Mendelian Inheritance in Man; see catalogs of autosomal dominant, autosomal recessive and X-linked phenotypes (Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University, Baltimore, MD and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, 2000. http://www.ncbi.nlm.nih.gov/omim/).
progression, to milder forms of later onset and slower progression (for a review, see Ref. 3). Inheritance may be autosomal dominant (LGMD1) or recessive (LGMD2). During the last decade, at least fifteen LGMD genes, six autosomal dominant and ten autosomal recessive, have been mapped. The autosomal dominant forms are relatively rare and probably represent less than 10% of all LGMD (3,4). The six autosomal dominant LGMD forms are: LGMD1A at 5q22, coding for the protein myotilin (5), LGMD1B at 1q11, coding for lamin A/C (6), LGMD1C at 3p25 coding for caveolin-3 (7,8), LGMD1D at 6q23 (9), LGMD1E at 7q (10), and LGMD1F at 5q31 (11).

Ten autosomal recessive forms have been mapped up to now and most of their protein products have been identified. Four of them, mapped at 17q21, 4q12, 13q12 and 5q33, respectively code for α-sarcoglycan (α-SG), β-SG, γ-SG and δ-SG, that are glycoproteins of the SG subcomplex of the dystrophin-glycoprotein complex (DGC) (12,13). Mutations in these genes cause LGMD2C, 2D, 2E and 2F, respectively, and constitute a distinct subgroup of LGMD, i.e., the sarcoglycanopathies (for reviews, see Refs. 3 and 4). Among the clinically milder forms, LGMD2A, at 15q15.1, codes for calpain 3 (14), LGMD2B, at 2p31, codes for dysferlin (15,16), and LGMD2G, at 17q11-12, codes for the sarcomeric telethonin (17,18) (Figure 1). Very recently, the fukitin-related protein (FKRP) gene, mapped at 19q13.3, was identified as the gene responsible for the LGMD2I form (19), as well as the severe form of congenital muscular dystrophy type 1 (CMD1C) (20); the protein TRIM32 has been identified as the gene product of the LGMD2H form (21) at 9q31-33 (22). LGMD2J was recently described in the Finnish population as the result of autosomal recessive mutations in the titin gene (23).

Protein studies can provide important information both for the diagnosis and the elucidation of physiological muscle pathways (24).

**Xp21 muscular dystrophies**

Dystrophin, the protein product of the DMD/BMD gene (1,2), is a large 427-kDa rod-shaped subsarcolemmal protein. Its amino terminus domain binds to actin, and the carboxyl terminus, which is rich in cysteine, links dystrophin to a complex of glycoproteins in the sarcolemma (12,13,25).

![Figure 1. Schematic representation of proteins from the sarcolemma, the sarcomere, the cytosol and the nucleus involved in the process of muscle degeneration in neuromuscular disorders. EDMD - Emery-Dreifuss muscular dystrophy; FKRP - fukutin-related protein; NOS - nitric oxide synthase; SMA - spinal muscular atrophy; SPN - sarcospan. See Table 1 for other abbreviations.](image-url)
The DGC is vital for normal muscle function.

The DGC forms a bridge across the muscle membrane, between the inner cytoskeleton (dystrophin) and the basal lamina (merosin). It has been suggested that DGC stabilizes the sarcolemma and protects muscle fibers from long-term contraction-induced damage and necrosis. The DGC consists of dystroglycan, SG and syntrophin/dystrobrevin subcomplexes (Figure 1). In addition to having a mechanical and structural function, the DGC has been recently suggested to play a role in cellular communication (26). Furthermore, it interacts with the sarcomeric network by binding dystrophin to F-actin (for a review, see Ref. 27).

Clinically, DMD patients show delayed onset of walking, a progressive weakness with difficulty in running, climbing stairs and jumping, frequent falls, and marked calf hypertrophy. The progressive muscle degeneration causes the loss of ambulation at about age 10 and death usually before the end of the second decade due to respiratory or cardiac failure. The milder BMD variant shows a less severe but more variable phenotype, ranging from a slightly less severe DMD-like condition to a very mild condition. Some patients may be able to walk throughout their lives. A patient is classified as DMD when wheelchair-dependent before the age of 13 years, and as BMD, when able to walk beyond age 16 (for a review, see Ref. 28).

About two thirds of DMD patients have a frame-shifting deletion in the dystrophin gene, while the remaining ones have point mutations or small deletions or rearrangements. All of these mutations lead to deficiency of the protein dystrophin in muscle (2).

Antibodies against epitopes in the N-terminal and C-terminal domains of dystrophin have been used in the analysis of more than 400 DMD patients from our laboratory. Almost all DMD patients are found to be dystrophin deficient when the C-terminal antibody is used. However, a variable proportion (4-30%) of dystrophin-positive isolated or grouped fibers (called revertant fibers) are observed in most of them, mainly with the N-terminal antibody (Figure 2). This small amount of dystrophin can be observed as faint bands by Western blotting, but is not
correlated with the clinical course (29-31). This observation should be taken into account before assessing the effect of any therapeutic trial with the replacement of dystrophin through gene or cell therapy.

A correlation between the amount of dystrophin and the severity of the phenotype has been suggested (2,29). However, in our experience, patients with an intermediate clinical phenotype between DMD and BMD (outlier patients) usually show the same dystrophin-deficient pattern as classical DMD (30,31).

In about 100 BMD patients, a positive immunofluorescence pattern was observed in ~90% of cases, with a variable degree of patchiness (Figure 2). Western blot detected bands of altered molecular weight or in reduced amount. Surprisingly, some mildly affected patients showed significant dystrophin deficiency, while some severely affected patients showed large amounts of the protein in muscle (32). In addition, BMD patients with mutations of exons 45 to 49 often present two dystrophin bands when N-terminal antibodies are used (Figure 2) (33).

Sarcoglycanopathies

The sarcoglycanopathies are usually the most severe forms of LGMD (34). The four known components of the SG complex include α-SG, β-SG, γ-SG, and δ-SG. They are assembled in a complex which is inserted into the membrane. Mutations in one of the four SG proteins cause LGMD2C, 2D, 2F, and 2E, respectively. Many different mutations have already been identified in all the SG genes, including missense, splicing and nonsense mutations, and small and large gene deletions [listed at http://www.dmd.nl]. Our group recently reported the spectrum of mutations in 35 Brazilian sarcoglycanopathy families (35). The main findings suggested that screening of sarcoglycanopathies in Brazil should start by detecting mutations α-SG/c.229C>T and γ-SG/c.521delT, followed by δ-SG/c.656delIC, since they were found to correspond to 26, 23 and 11% of the disease alleles. Therefore, screening for these three mutations would permit the diagnosis of ~60% of Brazilian sarcoglycanopathy patients (35).

In most muscle biopsies from patients with a primary sarcoglycanopathy, the primary loss or deficiency of any one of the four SG, β-SG and δ-SG in particular, leads to a secondary deficiency of the whole subcomplex (Figure 3) (3,4,26,36,37). However, exceptions may occur, such as the deficiency of γ-SG with a partial preservation of the other three SG in LGMD2C (37) or the partial deficiency of only α-SG with the retention of the other three in LGMD2D (36,38). The observation of a complete deficiency of one SG with partial deficiency of the others may help to indicate which gene should be first screened for mutations.

Patients with primary SG mutations and deficiency of the protein may have a secondary reduction in dystrophin, particularly patients with primary γ-SG deficiency. This

Figure 3. Immunofluorescence analysis for dystrophin and the four sarcoglycan (SG) proteins in a control, and in one sarcoglycan-deficient patient (LGMD2C).
suggests that γ-SG might interact more directly with dystrophin (37). Therefore, a relative dystrophin deficiency may occur in non-BMD, and this should be taken into consideration for differential diagnosis.

**Calpainopathy**

Calpain 3, a muscle-specific 94-kDa calcium-activated neutral protease 3, binds to titin. It is a cysteine protease which plays a role in the disassembly of sarcomeric proteins, but it may also have a regulatory role in the modulation of transcription factors. The loss of its function leads to activation of other proteases.

Mutations in the calpain 3 gene at 15q15 cause LGMD2A (14). LGMD2A patients present a wide range of distinct pathogenic mutations distributed along the entire length of the calpain 3 gene. Interestingly, Brazilian LGMD2A patients showed some prevalent mutations concentrated in six exons (39).

The study of calpain 3 protein in muscle at this time can only be carried out by Western blotting since the antibodies available do not react on sections. A first trial can be done by multiplex Western blot analysis for dystrophin, dysferlin and calpain (Figure 4). If a reduction is suspected, a new blot specific for calpain antibodies is performed on 13% gel, and the presence of the three possible calpain 3 bands is analyzed. *In vitro* degradation of the muscle extract may lead to misleading results which should be interpreted with care. LGMD2A patients can show total, partial, or more rarely, no calpain 3 deficiency at all, and no direct correlation has been observed between the amount of calpain and the severity of the phenotype. Very low levels or no expression of calpain 3 were observed in European and Brazilian patients with a clinical course varying from mild to severe (40,41). LGMD2A patients with missense mutations may present a faint or almost normal 94-kDa calpain band (39,40), suggesting that some mutations may affect protein function without eliminating the protein from muscle.

A normal amount of calpain was found in sarcoglycanopathies (40,41), and normal SG proteins were observed in calpain 3-deficient LGMD2A patients (37), suggesting no direct relationship between calpain 3 and the SG complex. In addition, normal calpain bands in LGMD2G patients also suggest no correlation with telethonin (42).

However, an unexpected reduction of calpain 3 was observed in LGMD2B patients, suggesting a possible association between calpain 3 and dysferlin, which requires further study (41,43,44). Subsequently, several studies have shown that a secondary reduction of calpain 3 may occur in other myopathies such as LGMD2I (45) and LGMD2J (23).

**Dysferlinopathies**

Dysferlin, coded by a gene on 2p12-14, is a ubiquitously expressed 230-kDa molecule
localized in the periphery of muscle fibers, linked to the sarcolemmal membrane (46). Dysferlin can be detected also in blood, skin and in chorionic villus biopsies (44,47).

Two distinct phenotypes are associated with mutations in this gene: Miyoshi myopathy, with a predominantly distal muscle wasting (16), and LGMD2B, with a proximal weakness (15). So far, due to the large size of the dysferlin gene (55 exons), only a few mutations have been identified, and no apparent hot spot for mutations has been found. Therefore, muscle protein analysis is essential for diagnostic purposes.

Protein analyses in LGMD2B have shown a total deficiency of dysferlin both by immunofluorescence and Western blotting (Figures 4 and 5). Although a partial deficiency has been reported in LGMD2B patients (46), dysferlin deficiency seems to be specific to LGMD2B in our patients, and has not been seen as a secondary effect in other forms of muscular dystrophy (44).

A normal localization and a normal molecular weight for dysferlin have been found in DMD and sarcoglycanopathies, suggesting no interaction between dysferlin and the DGC. A possible association between dysferlin and caveolin-3 has recently been described (48). It is important to point out that mutations in the caveolin-3 gene cause a rare form of autosomal dominant muscular dystrophy, as well as rippling muscle disease (7). Mutation in the caveolin-3 gene leads to a typical loss of caveolin immunolabeling, suggesting a dominant negative effect (7).

**Sarcomeric proteins in myopathies**

The sarcomere is the unit of skeletal and cardiac muscle contraction. In the past few years, many studies have focused on the role of skeletal and cardiac muscle proteins (49). Mutations in the genes for several sarcomeric proteins such as telethonin (18) and myotilin (5) have been detected in different forms of muscular dystrophies. In addition, mutations in five different sarcomeric genes, actin, tropomyosin 3 and 2, nebulin and troponin T1, have been identified as the cause of Nemaline myopathy, a congenital myopathy characterized by the presence of rod-like bodies inside muscle fibers (for a review, see Ref. 50). Clinically, Nemaline myopathy is associated with muscle weakness, respiratory and feeding difficulties at birth, an elongated face and skeletal deformities. The autosomal recessive form appears to be the most common one and is caused by mutations in the nebulin gene. Nebulin is a large protein of 800 kDa, and its C-terminus integrates into the Z-disk while the N-terminus projects into the I-band. Nebulin may provide a molecular template...
to regulate the length of the actin filament. We have recently identified a patient with
Nemaline myopathy, with a deficiency of only the SH3 domain of nebulin by Western
blot analysis (51).

Myotilin is a novel 57-kDa cytoskeletal
protein coded by a gene mapped at 5q3. It is
expressed in skeletal and cardiac muscle, and it co-localizes with α-actinin in the sarco-
meric I-band. Its N-terminal sequence is
unique, but the C-terminal half contains two
Ig-like domains homologous to domains in
titin. Titin acts as a molecular ruler for the
assembly of the sarcomere by providing spa-
tially defined binding sites for other sarco-
meric proteins. Mutations in the myotilin gene
cause the autosomal dominant form of
LGMD1A, but muscle myotilin protein is
apparently normal (5).

Telethonin is a sarcomeric protein of 19
kDa present in the Z-disk of the sarcomere of
striated and cardiac muscle (17). Mutations
in the telethonin gene at 17q cause LGMD2G
(18). Telethonin was found to be one of the
substrates of the serine kinase domain of
titin. The specific function of telethonin and
its interaction with other muscle proteins are
still unknown.

DNA analysis in six Brazilian patients
from four unrelated families showed that all
had the same frameshift mutation in the tele-
thonin gene and deficiency of the telethonin
protein in muscle (Figure 5). Since tele-
thoninopathy has not been reported in other
patients except the Brazilian ones, the exist-
ence and effect of other mutations are still
unknown.

Additional protein studies on these pa-
tients have shown normal expression of dystro-
phin, SG, dysferlin, calpain 3 and titin.
Immunofluorescence analysis for α-actinin-
2 and myotilin showed a normal cross-stria-
tion pattern, suggesting that at least part of
the Z-line of the sarcomere is preserved.
Utrastructural analysis confirmed the main-
tenance of the integrity of the sarcomeric
architecture. Therefore, mutations in the tele-
thonin gene do not seem to alter the sarco-
mere integrity (42).

The analysis of telethonin in muscle bi-
opseys from patients with LGMD2A,
LGMD2B, sarcoglycanopathies and DMD
showed normal localization, suggesting that
the deficiency of calpain, dysferlin, SG and
dystrophin does not seem to alter telethonin
expression (42). Telethonin was clearly pre-
ent in the rods in muscle fibers from patients
with Nemaline myopathy, confirming its lo-
calization in the Z-line of the sarcomere.

More recently, homozygous mutations in
the titin gene previously known to be respon-
sible for autosomal dominant tibial muscu-
lar dystrophy, a form prevalent in Finland,
were found to cause a proximal LGMD,
LGMD2J. A secondary reduction in calpain
3 was observed in these patients (23).

The identification of new protein compo-
nents of the sarcomere, such as ZASP, FATZ
and Ankrd2, using the two-hybrid or other
protein interaction techniques, is continu-
ously increasing. The role of most of these
proteins is still unknown. However, so far no
disease has been associated with any of them,
suggesting that total deficiency is probably
incompatible with life, and therefore that
they play an essential role in the constitu-
tion of the sarcomere.

Fukutin-related protein

Fukutin is the protein product of the
Fukuyama form of CMD, a multisystem dis-
ase affecting the brain as well as skeletal
and cardiac muscles. The function of fukutin
is still unknown. An FKRP was recently
identified, with sequence similarities to a
family of proteins involved in the glycosyla-
tion of cell surface molecules (19). Mutations
in the FKRP gene were identified in both
LGMD2I and CMD type 1C (CMD-1C)
(19,20), both previously mapped to an iden-
tical region on chromosome 19q13.3. CMD
is characterized by onset of symptoms within
the first few months of life, and in the 1C
form there is inability to walk. The LGMD21 form is characterized by a high variability in clinical course, with a spectrum of phenotypes ranging from a Duchenne-like disease course including cardiomyopathy to milder phenotypes with a slow progression (20). Secondary protein abnormalities are common in this group of diseases, including a reduction of α2-laminin labeling, mainly on immunoblots, reduced Western blot labeling for β1-laminin, and secondary reduction of calpain 3. A variable reduction of α-dystroglycan expression was also observed in skeletal muscle biopsies from affected individuals, with a reduction in molecular weight observed by immunoblotting, which could indicate a glycosylation defect associated with this disease. Therefore, until a proper antibody against FKRPs is developed, muscle protein analysis showing a relative secondary deficiency of α-dystroglycan and α2-laminin might suggest the diagnosis of LGMD21. This diagnosis should be confirmed by molecular analysis.

**Myotubularin**

Myotubularin is the protein product of the X-linked MTM1 gene. Mutations in this gene cause the most severe neonatal (and lethal) form of myotubular myopathy (XLMMTM) (for a review, see Ref. 52). XLMMTM is a congenital myopathy characterized by small muscle fibers with central nuclei resembling fetal myotubes. Through computer-based analysis of the predicted protein structure, myotubularin has been classified as a member of the protein tyrosine phosphatase family. It has been suggested that myotubularin is required for muscle cell differentiation, and that it exerts an important regulatory function during myogenesis.

**Nuclear proteins in neuromuscular disorders**

Emerin is a membrane-spanning 34-kDa serine-rich protein which is a component of the nuclear lamina associated with the nuclear envelope. The emerin gene has been mapped to Xq28, and mutations were found in the X-linked inherited Emery-Dreifuss dystrophy (53). One postulated function of emerin is to stabilize the nuclear membrane and provide structural support in an environment in which the nucleus is subject to mechanical stress.

Lamin A/C belongs to a family of nuclear laminar proteins which co-localizes with emerin. It is coded by a gene on chromosome 1 (1q11-23). Abnormalities in the gene for lamin A are associated with an autosomal dominant illness that is clinically identical to emerin deficiency, the LGMD1B form (54).

The survival motor neuron (SMN) gene product is the altered protein responsible for spinal muscular atrophy, an autosomal recessive neuromuscular disorder characterized by degeneration of motor neurons of the spinal cord. In humans, the SMN gene is found as two almost identical copies on chromosome 5, denoted SMN1 (telomeric) and SMN2 (centromeric), differing by just five nucleotides that undergo alternative splicing of exons 5 and 7 (55). SMN is both a cytoplasmic protein and a nuclear protein located in structures called “gems” (56). Studies characterizing the SMN protein are emerging.

**Extracellular matrix proteins**

α2-Laminin is a constituent of the basal lamina which links to dystroglycan and which provides structural support in the extracellular matrix. It is composed of three chains: α2, β1 and γ1. α2-Laminin deficiency due to mutations in the LAMA2 gene at 6q2 is the cause of the autosomal recessive CMD (57). α2-Laminin is totally deficient in muscle biopsies from patients with the severe CMD phenotype (Figure 6). Partial deficiencies have been described in patients with heterogeneity in the clinical picture (52). The protein is detected in skin biopsies as well as in
chorionic villi, and therefore is a very useful marker for prenatal diagnosis.

We have studied 20 patients affected by CMD and detected a total deficiency of α2-laminin in all of them using both the 80- and 300-kDa antibodies (58). In patients with partial deficiency, usually the 300-kDa antibody shows a more deficient pattern (59). A partial deficiency of only the 300-kDa α2-laminin antibody was recently detected in patients with the classical LGMD clinical course (60). In addition, secondary deficiency of α2-laminin has been found in CMD1C and LGMD21 (19,20). Screening for mutations in the LAMA2 gene can help elucidate the primary or secondary etiology of these deficiencies.

In addition to α2-laminin deficiency, marked alterations in the glycosylation of α-dystroglycan have been very recently associated with some forms of severe CMD (Fukuyama, Walker-Warburg, muscle-eye-brain and FKRP forms). Mutations in genes with glucosyltransferase activity have been identified as responsible for these diseases, suggesting that abnormal processing of α-dystroglycan may be central to the pathogenesis of a significant number of genetic conditions (61).

Recessive mutations in the COL6A2 gene cause Ullrich CMD, a severe muscle weakness disease associated with multiple joint contractures and deficiency of collagen VI in tissues. On the other hand, dominant mutations in the same gene may cause Bethlem myopathy, a skeletal muscle myopathy with a large spectrum of clinical variability also associated with contractures. Therefore, autosomal recessive or dominant mutations in the same gene may cause clinically different diseases (62).

**Protein study for differential diagnosis**

Testing for defective protein expression is a powerful tool for deciding where to start the search for gene mutations, particularly in the more prevalent forms of neuromuscular disorders.

Male patients with suspected X-linked dystrophy are first tested for deletions in the dystrophin gene by DNA analysis in blood samples, because this is a less invasive test. The identification of a gene deletion will confirm the diagnosis of DMD/BMD in about 60% of cases. If no deletion is detected, a muscle biopsy is required for the analysis of muscle proteins in an attempt to elucidate the possible diagnosis. Dystrophin is the first protein to be tested, using N- and C-terminal epitope antibodies. A significant deficiency of dystrophin is suggestive of DMD or severe BMD. Complementary Western blot analysis will confirm the amount of protein present, and a possible prognosis based on dystrophin quantity and the presence or absence of the different domains.

If an autosomal form is suspected, complementary studies for α-SG and γ-SG in a double reaction with an N-terminal antibody for dystrophin are conducted. If a deficiency of any of the SG is detected, additional studies for β-SG and δ-SG are conducted to confirm a possible sarcoglycanopathy. For the final diagnosis of a sarcoglycanopathy, mutation screening should start with α-SG since this is the cause of the most prevalent sarcoglycanopathy. If γ-SG is predominantly absent, a γ-sarcoglycanopathy should be suspected first.

Another possibility for male patients who are dystrophin-positive, but with early contractures and cardiomyopathy could be Emery-Dreifuss muscular dystrophy. In such cases, immunofluorescence analysis for emerin should be done, and a negative nuclear labeling would confirm the diagnosis.

Additional immunofluorescence analyses for α2-laminin using the 300-kDa antibody should be done in more severely affected patients. The diagnosis of total or partial α2-laminin deficiency is confirmed using an additional antibody (80 kDa) against
the N-terminal region. Partial α2-laminin deficiencies might be associated with a diagnosis of MDC1C or LGMD2I, but the deficiency needs to be confirmed by mutational analysis. Western blot analysis for α-dystroglycan glycosylation can also add some information about new genes related to alterations in this process, such as LGMD2I, and to other forms of CMD.

In adult onset muscular dystrophy forms, multiplex Western blot analysis for dystrophin, calpain and dysferlin, as well as telethonin analysis by immunofluorescence, has proved to be very useful for preliminary diagnosis of muscular dystrophy. A dystrophin deficiency is first suggestive of Xp21 muscular dystrophy. However, small reductions can also be observed in sarcoglycanopathies and LGMD2I. Calpain 3 may occur as a secondary effect of other forms of muscular dystrophy, but dysferlin and telethonin deficiency have been shown so far to be the consequence of their respective primary gene defect. Therefore, the absence of dysferlin or telethonin in a muscle biopsy strongly suggests a diagnosis of LGMD2B or LGMD2G, respectively.

When a deficiency of calpain 3 is detected and no mutations in the calpain 3 gene are found, the possibility of dysferlin-, FKRP- and titin-associated conditions should be considered, mainly if the deficiency is partial.

If no protein or DNA alterations are found in patients with a clinical diagnosis of LGMD, the possibility of spinal muscular atrophy should be considered due to the clinical overlap between these diseases.

For the remaining proteins described here (mainly the sarcomeric ones), for which no clear deficiency has been previously described associated with their respective primary defect, protein testing is not useful for diagnostic purposes. In this respect, the development of new methodologies for the identification of subtle protein alterations are of the utmost importance, not only for the diagnosis, but also for understanding interactions among proteins in order to elucidate genotype/phenotype interaction in neuromuscular diseases.

Acknowledgments

The collaboration of the following persons is gratefully acknowledged: Marta Cânovas for invaluable technical help, and Dr. Maria Rita Passos-Bueno, Dr. Eloisa S. Moreira, Dr. Rita C.M. Pavanello, Dr. Ivo Pavanello, Dr. Acary S.B. Oliveira, Dr. Edmar Zanotelli, Cleber da Silva Costa, Viviane P. Muniz, Telma Gouveia, Bruno Lima, Helena Lima, Lydia U. Yamamoto, Flavia de Paula, Alessandra Starling, Antonia Cerqueira, Constância Urbani, Janet Tajchman, and Ms. Lucete Cesana. We would also like to thank the following researchers, who kindly provided specific antibodies: L.V.B. Anderson, A. Beggs, J. Chamberlain, L.M. Kunkel, C. Bonnemann, E.E. McNally, V. Nigro, Z. Labeit, O. Carpen, G. Faulkner, G. Valle, E. Hoffmann, R. Worton, E. Ozawa, K. Campbell, N. Thi Man, and G. Morris. Very special thanks are due to Dr. Zubrzycka-Gaarm (in memoriam), Dr. Peter Ray and Dr. Ron Worton, who opened their laboratory to introduce us to Western blot studies.

References


28. Vainzof M, Moreira ES, Canovas M, Suzuki OT, Pavanello RCM,


